Omics Approaches in Breast Cancer
Towards Next-generation Diagnosis, Prognosis, and Therapy
Elsewhere $335 $157 Save $178.00 (53%)
Free shipping Australia wide
|Format: ||Hardback, 573 pages|
|Other Information: ||25 black & white illustrations, 35 colour illustrations, biography|
|Published In: ||India, 14 November 2014|
Breast cancer is the most common cancer in females that accounts for highest cancer specific deaths worldwide. In the last few decades research has proven that breast cancer can be treated if diagnosed at early stages and proper therapeutic strategy is adopted. Omics-based recent approaches have unveiled the molecular mechanism behind the breast tumorigenesis and aid in identification of next-generation molecular markers for early diagnosis, prognosis and even the effective targeted therapy. Significant development has taken place in the field of omics in breast cancer in the last decade. The most promising omics approaches and their outcomes in breast cancer have been presented in this book for the first time. The book covers omics technologies and budding fields such as breast cancer miRNA, lipidomics, epigenomics, proteomics, nutrigenomics, stem cell, pharmacogenomics and personalized medicine and many more along with conventional topics such as breast cancer management etc. It is a research-based reference book useful for clinician-scientists, researchers, geneticists and health care industries involved in various aspects of breast cancer. The book will also be useful for students of biomedicine, pathology and pharmacy.
Table of Contents
Part I: Omics Approaches in Breast Cancer Omics Technologies Applied in Breast Cancer Research.- Omics of Hereditary Breast Cancer.- Oncogenes and Tumor Supressor Genes as a Biomarker in Breast Cancer.- Breast Cancer Genomics.- Epigenomics of Breast Cancer.- Nutrigenomics in Breast Cancer.- Long Non-coding RNAs in Breast Cancer: Implications for Pathogenesis, Diagnosis and Therapy.- Breast Cancer MicroRNAs: Clinical Biomarkers for the Diagnosis and Treatment Strategies.- Breast Cancer Proteomics.- Metabolomics in Breast Cancer.- Lipidomics in Breast Cancer.- Breast Cancer Stem Cells and Cellomics.- Omics of Male Breast Cancer.- Omics of Chemoresistant and Metastatic Breast Cancer.- Animal Models of Breast Cancer.- In Silico Disease Models of Breast Cancer.- Systems Biology and Integrative Omics in Breast Cancer.- Gynecologic Considerations for Women with Breast Cancer.- Imaging Technologies and Applications in Early Diagnosis and Prognosis for Breast Cancer.- Breast Cancer Biomarkers for Risk Assessment, Screening, Detection, Diagnosis and Prognosis.- Breast Circulating Tumor Cells: Potential Biomarkers for Breast Cancer Diagnosis and Prognosis Evaluation.- Molecular Diagnosis Of Metastasizing Breast Cancer Based Upon Liquid Biopsy.- Exhaled Volatile Organic Compounds as Non-Invasive Markers in Breast Cancer.- Breast Cancer Therapy-Classical Therapy, Drug Targets and Targeted Therapy.- Pharmacogenomics-Pharmacoepigenomics of Breast Cancer Therapy: Clinical Implications.- Breast Cancer Gene Therapy.- Clinical Trial Endpoints in Breast Cancer.
About the Author
Dr Debmalya Barh is the founder of Institute of Integrative Omics and Applied Biotechnology (IIOAB) at Nonakuri, Tamluk, West Bengal, India. His core competencies include bioinformatics, genome, genomics and proteomics, cell signaling, integrative omics based marker and target discovery, cancer pharmacogenomics, personalized medicine, cardiovascular and infectious diseases. He has been a consultant for three top healthcare and diagnostic companies in USA. He is the reviewer/editorial board member of many journals like CMAJ, Molecular Medicine, Bioinformatics, BMC Genomics, BMC Systems Biology, Journal of Medical Informatics, Current Oncology, Gene Therapy, J. Cardiovascular Dis Res, J Integrated Omics, AIOAB. He has several scientific publications including genome sequences, journal articles, book chapters and reference books.
|Publisher: ||Springer, India, Private Ltd|
|Dimensions: ||25.0 x 17.0 centimetres (0.51 kg)|